{"id":"W4417016321","doi":"10.1182/blood-2025-8246","title":"Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Tolerability; Multiple myeloma; Phases of clinical research; Pharmacokinetics; Pharmacodynamics; Bortezomib; Drug","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002652477,0.00219914,0.002157364,0.0004828721,0.0006248635,0.001521573,0.001355028,0.002265024,0.007981721],"category_scores_gemma":[0.001168841,0.000724213,0.001803094,0.000489827,0.001069417,0.001784248,0.0005432594,0.005079345,0.002138133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001188827,"about_ca_system_score_gemma":0.001911279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008810532,"about_ca_topic_score_gemma":0.00177674,"domain_scores_codex":[0.9993573,0.0003049186,0.0000302281,0.0001215717,0.00007051561,0.0001154516],"domain_scores_gemma":[0.9991469,0.0001009259,0.0001696008,0.00008219258,0.00007353193,0.0004268312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7436284,0.08925359,0.006759022,0.001493238,0.002664771,0.0004268854,0.0004036285,0.002640143,0.04757943,0.0006698651,0.01311458,0.09136649],"study_design_scores_gemma":[0.7708369,0.2132142,0.006615486,0.00005325282,0.0004074783,0.000326797,0.00005701231,0.001177489,0.002197325,0.0003973862,0.004685096,0.00003167843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9649705,0.005778398,0.001856415,0.003253855,0.0003982297,0.01110404,0.006726237,0.000438374,0.005474011],"genre_scores_gemma":[0.948819,0.003896601,0.006956811,0.005043959,0.0005226575,0.01411694,0.01162459,0.0001508129,0.008868723],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.007981721,"threshold_uncertainty_score":0.02670151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01926033292288509,"score_gpt":0.3344037877665396,"score_spread":0.3151434548436545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}